Two Satiety Systems, One Goal

GLP-1 and amylin are both satiety hormones, but they act through different receptors and pathways. Combining them targets two independent levers on appetite — which in trials produces greater weight loss than either alone.

This is one of the better-justified combinations in metabolic research, with actual clinical trial data behind the pairing. Members discuss it as a model of rational combination design: distinct mechanisms, additive benefit.